Cargando…

In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2(+) breast cancer

Detection of minor genetically distinct subpopulations within tumors is a key challenge in cancer genomics. Here we report STAR-FISH (Specific-To-Allele PCR – FISH), a novel method for the combined detection of single nucleotide and copy number alterations in single cells in intact archived tissues....

Descripción completa

Detalles Bibliográficos
Autores principales:	Janiszewska, Michalina, Liu, Lin, Almendro, Vanessa, Kuang, Yanan, Paweletz, Cloud, Sakr, Rita A., Weigelt, Britta, Hanker, Ariella B., Chandarlapaty, Sarat, King, Tari A., Reis-Filho, Jorge S., Arteaga, Carlos L., Park, So Yeon, Michor, Franziska, Polyak, Kornelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589505/ https://www.ncbi.nlm.nih.gov/pubmed/26301495 http://dx.doi.org/10.1038/ng.3391

Ejemplares similares

Mouse models and anti-HER2 therapies
por: Hanker, Ariella B., et al.
Publicado: (2013)

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2021)

Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity
por: Marusyk, Andriy, et al.
Publicado: (2014)

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
por: She, Qing-Bai, et al.
Publicado: (2008)

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023)

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2
por: Moynahan, Mary Ellen, et al.
Publicado: (2017)

Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors
por: Rye, Inga H., et al.
Publicado: (2018)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
por: Smith, Alison E., et al.
Publicado: (2021)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
por: Peixoto, Ana, et al.
Publicado: (2023)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
por: Chandarlapaty, Sarat, et al.
Publicado: (2009)

Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification
por: Pai, Shih-Min, et al.
Publicado: (2021)

HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression
por: Luoh, Shiuh-Wen, et al.
Publicado: (2013)

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma
por: Walentynowicz, Kacper A., et al.
Publicado: (2023)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Amplification of HER2 is a marker for global genomic instability
por: Ellsworth, Rachel E, et al.
Publicado: (2008)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer
por: Jørgensen, Jan Trøst, et al.
Publicado: (2017)

HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma
por: Raj, Nisha, et al.
Publicado: (2018)

HER2 Amplification in p53-Mutated Endometrial Carcinomas
por: Balestra, Ambre, et al.
Publicado: (2023)

HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
por: Seo, An Na, et al.
Publicado: (2014)

Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer
por: Dupouy, Diego G., et al.
Publicado: (2016)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
por: Gaibar, María, et al.
Publicado: (2022)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
por: Cataldo, Maria Letizia, et al.
Publicado: (2023)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
por: Ng, Charlotte KY, et al.
Publicado: (2015)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
por: Serra, V, et al.
Publicado: (2011)

Determination of HER2 Amplification Status on Tumour DNA by Digital PCR
por: Garcia-Murillas, Isaac, et al.
Publicado: (2013)

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
por: Bar, Julia K, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t0f9tedrl4ap50kj8sskgh8qfd